• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunity . SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

tetano

Editor, Senior Moderator
Immunity


. 2020 Nov 21;S1074-7613(20)30496-9.
doi: 10.1016/j.immuni.2020.11.009. Online ahead of print.
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation


Katlyn Lederer[SUP] 1 [/SUP], Diana Casta?o[SUP] 2 [/SUP], Daniela G?mez Atria[SUP] 3 [/SUP], Thomas H Oguin 3rd[SUP] 4 [/SUP], Sidney Wang[SUP] 1 [/SUP], Tomaz B Manzoni[SUP] 1 [/SUP], Hiromi Muramatsu[SUP] 5 [/SUP], Michael J Hogan[SUP] 6 [/SUP], Fatima Amanat[SUP] 7 [/SUP], Patrick Cherubin[SUP] 1 [/SUP], Kendall A Lundgreen[SUP] 1 [/SUP], Ying K Tam[SUP] 8 [/SUP], Steven H Y Fan[SUP] 8 [/SUP], Laurence C Eisenlohr[SUP] 9 [/SUP], Ivan Maillard[SUP] 3 [/SUP], Drew Weissman[SUP] 5 [/SUP], Paul Bates[SUP] 1 [/SUP], Florian Krammer[SUP] 10 [/SUP], Gregory D Sempowski[SUP] 11 [/SUP], Norbert Pardi[SUP] 5 [/SUP], Michela Locci[SUP] 12 [/SUP]



Affiliations

Abstract

The deployment of effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to eradicate the coronavirus disease 2019 (COVID-19) pandemic. Many licensed vaccines confer protection by inducing long-lived plasma cells (LLPCs) and memory B cells (MBCs), cell types canonically generated during germinal center (GC) reactions. Here, we directly compared two vaccine platforms-mRNA vaccines and a recombinant protein formulated with an MF59-like adjuvant-looking for their abilities to quantitatively and qualitatively shape SARS-CoV-2-specific primary GC responses over time. We demonstrated that a single immunization with SARS-CoV-2 mRNA, but not with the recombinant protein vaccine, elicited potent SARS-CoV-2-specific GC B and T follicular helper (Tfh) cell responses as well as LLPCs and MBCs. Importantly, GC responses strongly correlated with neutralizing antibody production. mRNA vaccines more efficiently induced key regulators of the Tfh cell program and influenced the functional properties of Tfh cells. Overall, this study identifies SARS-CoV-2 mRNA vaccines as strong candidates for promoting robust GC-derived immune responses.

Keywords: COVID-19; SARS-CoV-2; T follicular helper cells; germinal center B cells; germinal centers; mRNA vaccines; neutralizing antibodies.
 
Back
Top Bottom